arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

REPLIGEN CORP

RGEN
$168.52 ▼ -9.67 (-5.43%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
60
Health
Fair
Neutral
auto_awesome

Analytical Summary

REPLIGEN CORP shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $9.5M
Dividend Yield —
Revenue Growth 16.4% ↗
Op. Margin 7.5% ↗
ROIC 1.6% ↗
FCF / Share None
Trailing P/E 193.7x
Price / Book 4.5x
FCF Yield —
Debt / Equity 0.26
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$738.26M
↑ +16.4% —
Net Income Profit after all expenses
$48.89M
↑ +291.6% —
Operating Margin Operating profit as % of sales
7.5%
↑ +235.0% 50th
FCF / Share Free cash flow per share
$0.76
↓ -24.1% —
Long-Term Debt Long-term obligations
$542.21M
↑ +3.2% —

Health Breakdown

Profitability ↓
57
Returns ↓
48
Financial Health ↓
65
Cash Quality ↑
85

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters